Table 3

Multivariable Cox regression analysis of 5-year survival of the first TNFi in AS and uSpA

ASuSpA
BSEp ValueHR (95% CI)BSEp ValueHR (95% CI)
Age (per 10 years)0.0120.0360.7391.01 (0.94 to 1.09)0.0210.0350.5521.02 (0.95 to 1.09)
Sex (ref. female)−0.4120.094<0.0010.66 (0.55 to 0.80)−0.3810.088<0.0010.68 (0.57 to 0.81)
csDMARD comedication (ref. none)−0.3490.094<0.0010.71 (0.59 to 0.85)−0.2010.0860.0200.82 (0.69 to 0.97)
TNFi type0.037<0.001
 ADA vs IFX−0.1070.1070.3170.90 (0.73 to 1.11)−0.3650.1110.0010.69 (0.56 to 0.86)
 ETN vs IFX−0.2880.1120.0100.75 (0.60 to 0.93)−0.3390.0990.0010.71 (0.59 to 0.86)
Start year 2007–2010 vs 2003–20060.2030.0970.0371.22 (1.01 to 1.48)0.2590.0920.0051.30 (1.08 to 1.55)
Number of hospital days*0.0080.0030.0081.01 (1.00 to 1.01)0.0050.0020.0061.00 (1.00 to 1.01)
Number of outpatient visits*0.0160.0060.0101.02 (1.00 to 1.03)0.0050.0050.2641.01 (1.00 to 1.01)
Disposable income (per 1000 €)†−0.0050.0040.1460.99 (0.99 to 1.00)−0.0020.0030.4591.00 (0.99 to 1.00)
Education0.0870.032
 10–12 years vs ≤9 years−0.0750.1190.5320.93 (0.73 to 1.17)−0.1310.1200.2750.88 (0.69 to 1.11)
 >12 years vs ≤9 years−0.2530.1340.0600.78 (0.60 to 1.01)−0.3550.1310.0070.70 (0.54 to 0.91)
 Missing vs ≤9 years0.9370.7190.1922.55 (0.62 to 10.4)−10.29102.10.9200.00 (0.00 to ∞)
  • *During the period 2 years prior to TNFi start.

  • †2008 data used for patients started on TNFi in 2010, data from the year prior for all other patients.

  • ADA, adalimumab; AS, ankylosing spondylitis; csDMARD, conventional synthetic disease modifying antirheumatic drug; ETN, etanercept; IFX, infliximab; TNFi, tumour necrosis factor inhibitor; uSpA, undifferentiated spondyloarthritis.